Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose tapering and early discontinuation to increase cost-effectiveness of pembrolizumab in non-small cell lung cancer (Trial 1)
2020-000493-15Phase 3Active
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: 1-year survival rate. Started Mar 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000493-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000493-15.